Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2

• & needed ICU admission.

Exclusion Criteria:

• Chronic renal failure

• Liver cirrhosis

• Bleeding disorders or current anticoagulant therapy

• Pregnancy or breastfeeding

• Impaired color vision

• Severe vascular ischemia, history of venous thrombosis & pulmonary embolism

• Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission

• Allergy to tranexamic acid (TXA)